Chimerix

Chimerix is developing novel antiviral therapies that have the potential to transform patient care across multiple settings, including transplant, oncology, acute care, and global health. The company’s lead candidate, CMX001, is being developed as a potential broad-spectrum antiviral for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. To date, more than 350 individuals have received CMX001, with a growing body of evidence supporting the drug's antiviral activity in humans.